HCC cells that are resistant to sorafenib exhibit abnormally high activation of the Akt pathway, which is critical to cell survival through promotion of cell growth and division, stimulation of angiogenesis, and inhibition of apoptosis, and blocking Akt can potentially reverse this resistance [63,64]. Here, AKT1 is linked to hepatocellular carcinoma.